Challenging Axillary Lymph Nodes on PET/CT in Cancer Patients throughout COVID-19 Vaccination Era
- Authors: Giordano A.1, Gallicchio R.1, Milella M.1, Storto R.1, Nardelli A.1, Pellegrino T.1, Nappi A.1, Di Cosola M.2, Storto G.1
-
Affiliations:
- Department of Nuclear Medicine, IRCCS CROB Referral Cancer Center of Basilicata
- Department of Head and Neck Pathology, University of Foggia,
- Issue: Vol 30, No 10 (2024)
- Pages: 798-806
- Section: Immunology, Inflammation & Allergy
- URL: https://vestnikugrasu.org/1381-6128/article/view/645431
- DOI: https://doi.org/10.2174/0113816128246329231016091519
- ID: 645431
Cite item
Full Text
Abstract
Background:The unexpected detection of axillary lymphadenopathy (AxL) in cancer patients (pts) represents a real concern during the COVID-19 vaccination era. Benign reactions may take place after vaccine inoculation, which can mislead image interpretation in patients undergoing F-18-FDG, F-18-Choline, and Ga-68-DOTATOC PET/CT. They may also mimic loco-regional metastases or disease. We assessed PET/CT findings after COVID-19 first dose vaccination in cancer patients and the impact on their disease course management.
Methods:We evaluated 333 patients undergoing PET/CT (257 F-18-FDG, 54 F-18-Choline, and 23 Ga-68 DOTATOC) scans after the first vaccination with mRNA vaccine (Pfizer-BioNTech) (study group; SG). The uptake index (SUVmax) of suspected AxL was defined as significant when the ratio was > 1.5 as compared to the contralateral lymph nodes. Besides, co-registered CT (Co-CT) features of target lymph nodes were evaluated. Nodes with aggregate imaging positivity were further investigated.
Results:Overall, the prevalence of apparently positive lymph nodes on PET scans was 17.1% during the vaccination period. 107 pts of the same setting, who had undergone PET/CT before the COVID-19 pandemic, represented the control group (CG). Only 3 patients of CG showed reactive lymph nodes with a prevalence of 2.8% (p < 0.001 as compared to the vaccination period). 84.2% of SG patients exhibited benign characteristics on co-CT images and only 9 pts needed thorough appraisal.
Conclusion:The correct interpretation of images is crucial to avoid unnecessary treatments and invasive procedures in vaccinated cancer pts. A detailed anamnestic interview and the analysis of lymph nodes CT characteristics, after performing PET/CT, may help to clear any misleading diagnosis.
Keywords
About the authors
Alessia Giordano
Department of Nuclear Medicine, IRCCS CROB Referral Cancer Center of Basilicata
Email: info@benthamscience.net
Rosj Gallicchio
Department of Nuclear Medicine, IRCCS CROB Referral Cancer Center of Basilicata
Email: info@benthamscience.net
Mariarita Milella
Department of Nuclear Medicine, IRCCS CROB Referral Cancer Center of Basilicata
Email: info@benthamscience.net
Rebecca Storto
Department of Nuclear Medicine, IRCCS CROB Referral Cancer Center of Basilicata
Email: info@benthamscience.net
Anna Nardelli
Department of Nuclear Medicine, IRCCS CROB Referral Cancer Center of Basilicata
Email: info@benthamscience.net
Teresa Pellegrino
Department of Nuclear Medicine, IRCCS CROB Referral Cancer Center of Basilicata
Email: info@benthamscience.net
Antonio Nappi
Department of Nuclear Medicine, IRCCS CROB Referral Cancer Center of Basilicata
Email: info@benthamscience.net
Michele Di Cosola
Department of Head and Neck Pathology, University of Foggia,
Email: info@benthamscience.net
Giovanni Storto
Department of Nuclear Medicine, IRCCS CROB Referral Cancer Center of Basilicata
Author for correspondence.
Email: info@benthamscience.net
References
- Viscusi WK. Pricing the global health risks of the COVID-19 pandemic. J Risk Uncertain 2020; 61(2): 101-28. doi: 10.1007/s11166-020-09337-2 PMID: 33162671
- Jabłońska K, Aballéa S, Toumi M. The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. Public Health 2021; 198: 230-7. doi: 10.1016/j.puhe.2021.07.037 PMID: 34482101
- Tanne JH. COVID-19: FDA approves Pfizer-BioNTech vaccine in record time. BMJ-Brit Med J 2021; 374: n2096.
- Iacobucci G. COVID-19: FDA set to grant full approval to Pfizer vaccine without public discussion of data. BMJ-Brit Med J 2021; 374: n2086.
- Su S, Du L, Jiang S. Learning from the past: Development of safe and effective COVID-19 vaccines. Nat Rev Microbiol 2021; 19(3): 211-9. PMID: 33067570
- Fanciullino R, Ciccolini J, Milano G. COVID-19 vaccine race: watch your step for cancer patients. Br J Cancer 2021; 124(5): 860-1. PMID: 33288844
- Rodríguez-Alfonso B, Ruiz Solís S, Silva-Hernández L, et al. 18F-FDG-PET/CT in SARS-CoV-2 infection and its sequelae. Rev Esp Med Nucl Imagen Mol 2021; 40: 299-309.
- Ahn RW, Mootz AR, Brewington CC, Abbara S. Axillary lymphadenopathy after mRNA COVID-19 vaccination. Radiol Cardiothorac Imaging 2021; 3(1): e210008. PMID: 33778667
- McIntosh LJ, Bankier AA, Vijayaraghavan GR, Licho R, Rosen MP. COVID-19 vaccination-related uptake on FDG PET/CT: An emerging dilemma and suggestions for management. AJR Am J Roentgenol 2021; 217(4): 975-83. doi: 10.2214/AJR.21.25728 PMID: 33646823
- Seely JM, Barry MH. The Canadian society of breast imaging/Canadian association of radiologists recommendations for the management of axillary adenopathy in patients with recent COVID-19 vaccination. Can Assoc Radiol J 2021; 72: 601-2. doi: 10.1177/0846537121998949 PMID: 34311551
- Lehman CD, DAlessandro HA, Mendoza DP, Succi MD, Kambadakone A, Lamb LR. Unilateral lymphadenopathy after COVID-19 vaccination: A practical management plan for radiologists across specialties. J Am Coll Radiol 2021; 18(6): 843-52. doi: 10.1016/j.jacr.2021.03.001 PMID: 33713605
- Storto G, Nicolai E, Salvatore M. 18FFDG-PET-CT for early monitoring of tumor response: when and why. Q J Nucl Med Mol Imaging 2009; 53(2): 167-80. PMID: 19293765
- Storto G, De Renzo A, Pellegrino T, et al. Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Radiology 2010; 254(1): 245-52. doi: 10.1148/radiol.09090603 PMID: 20032155
- Treglia G. Diagnostic performance of 18F-FDG PET/CT in infectious and inflammatory diseases according to published meta-analyses. Contrast Media Mol Imaging 2019; 2019: 1-12. doi: 10.1155/2019/3018349 PMID: 31427907
- Casali M, Lauri C, Altini C, et al. State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation. Clin Transl Imaging 2021; 9(4): 299-339. doi: 10.1007/s40336-021-00445-w PMID: 34277510
- Oprea-Lager DE, Vincent AD, van Moorselaar RJA, et al. Dual-phase PET-CT to differentiate 18FFluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer. PLoS One 2012; 7(10): e48430. doi: 10.1371/journal.pone.0048430 PMID: 23119014
- Weiler-Sagie M, Half EE. 68GaGa-DOTA-TATE uptake due to COVID-19 vaccination. Eur J Nucl Med Mol Imaging 2021; 48(11): 3743-4. doi: 10.1007/s00259-021-05414-z PMID: 34021394
- Thomassen A, Lerberg Nielsen A, Gerke O, Johansen A, Petersen H. Duration of 18F-FDG avidity in lymph nodes after pandemic H1N1v and seasonal influenza vaccination. Eur J Nucl Med Mol Imaging 2011; 38(5): 894-8. doi: 10.1007/s00259-011-1729-9 PMID: 21340453
- Smith MV, Yang M. Reactive axillary lymphadenopathy to COVID-19 vaccination on 18 F-FDG PET/CT. J Nucl Med Technol 2021; 49(3): 286-7. doi: 10.2967/jnmt.121.262008 PMID: 33820864
- Nawwar AA, Searle J, Hopkins R, Lyburn ID. False-positive axillary lymph nodes on FDG PET/CT resulting from COVID-19 immunization. Clin Nucl Med 2021; 46(12): 1004-5. doi: 10.1097/RLU.0000000000003657 PMID: 33883486
- Schroeder DG, Jang S, Johnson DR, et al. Frequency and characteristics of nodal and deltoid FDG and (11)C-Choline uptake on PET performed after COVID-19 vaccination. AJR Am J Roentgenol 2021; 217(5): 1206-16. doi: 10.2214/AJR.21.25928 PMID: 34009000
- Eifer M, Eshet Y. Imaging of COVID-19 vaccination at FDG PET/CT. Radiology 2021; 299(2): E248. doi: 10.1148/radiol.2020210030 PMID: 33507123
- Cocco G, Delli Pizzi A, Fabiani S, et al. Lymphadenopathy after the anti-COVID-19 vaccine: multiparametric ultrasound findings. Biology (Basel) 2021; 10(7): 652. doi: 10.3390/biology10070652 PMID: 34356507
- Tan NJH, Tay KXJ, Wong SBJ, Nga ME. COVID‐19 post‐vaccination lymphadenopathy: Report of cytological findings from fine needle aspiration biopsy. Diagn Cytopathol 2021; 49(12): E467-70. doi: 10.1002/dc.24863 PMID: 34432391
- Albano D, Bertagna F, Alongi P, et al. Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study. Eur J Nucl Med Mol Imaging 2021; 48(9): 2871-82. doi: 10.1007/s00259-021-05219-0 PMID: 33560453
- Shin M, Hyun CY, Choi YH, Choi JY, Lee KH, Cho YS. COVID-19 vaccination-associated lymphadenopathy on FDG PET/CT: Distinctive features in adenovirus-vectored vaccine. Clin Nucl Med 2021; 46(10): 814-9. doi: 10.1097/RLU.0000000000003800 PMID: 34115709
- Eshet Y, Tau N, Alhoubani Y, Kanana N, Domachevsky L, Eifer M. Prevalence of increased FDG PET/CT axillary lymph node uptake beyond 6 weeks after mRNA COVID-19 vaccination. Radiology 2021; 300(3): E345-7. doi: 10.1148/radiol.2021210886 PMID: 33904778
- Su N, Wiefels C, Klein R, Zeng W, Abbaspour F. Intensity of hypermetabolic axillary lymph nodes in oncologic patients in relation to timeline following COVID-19 vaccination. J Med Imaging Radiat Sci 2022; 53(2): 219-25. doi: 10.1016/j.jmir.2022.01.004 PMID: 35131216
- Weissman J, Bartel T. COVID-19 messenger ribonucleic acid vaccination and abnormal radiopharmaceutical uptake in the axilla visualized on 68Ga-DOTATATE positron-emission tomography/computed tomography. World J Nucl Med 2021; 20(4): 392-4. doi: 10.4103/wjnm.wjnm_54_21 PMID: 35018159
- Tsumura Y, Asakura K, Takahashi I, et al. New mimic of relapse or regional lymph node metastasis in a cancer survivor: A case of mRNA COVID-19 vaccine-induced lymphadenitis with high FDG uptake. Immunol Med 2021; 16: 1-3. PMID: 34915816
- Kirienko M, Biroli M, Pini C, Gelardi F, Sollini M, Chiti A. COVID-19 vaccination, implications for PET/CT image interpretation and future perspectives. Clin Transl Imaging 2022; 10(6): 631-42. doi: 10.1007/s40336-022-00521-9 PMID: 35992042
- Sollini M, Gelardi F, Biroli M, Chiti A. Patients findings after COVID-19 infection and vaccinations: What to expect from 18FFDG PET/CT. Eur J Nucl Med Mol Imaging 2022; 49(3): 791-5. doi: 10.1007/s00259-021-05652-1 PMID: 34928399
- Calabria F, Bagnato A, Guadagnino G, et al. COVID-19 vaccine related hypermetabolic lymph nodes on PET/CT: Implications of inflammatory findings in cancer imaging. Oncol Res 2023; 31(2): 117-24. doi: 10.32604/or.2023.027705 PMID: 37304242
- Zoughbor SH, AlRasbi Z, Yousif A, et al. Unilateral axillary lymphadenopathy in cancer patients post-COVID-19 vaccination: Review and case series. Case Rep Oncol 2023; 16(1): 188-203. doi: 10.1159/000529913 PMID: 37033700
Supplementary files
